MyCasEv
Industry: Industry: CRISPR technology
CRISPR technology allows for genomic editing and holds great promise for combating cancers. However, the technology lacks complete accuracy, creating the possibility for off-target effects and adverse immune response.
A solution to these problems, pioneered by MyCasEv, involves using extracellular vesicles – particles that move and communicate between cells – to carry CRISPR “machinery” (a specialized protein) to the targeted area.
The MyCasEv approach holds great promise, especially for treating castration-resistant prostate cancer, an especially deadly form of cancer that currently has no effective therapies.
